We’re Delin Ventures, the venture arm of Delin Capital. We invest in and build life sciences companies, and because we’re backed by permanent capital, we’re never in a rush. We’re here to walk alongside founders for the long run, from the first breakthrough to real-world scale.
We believe breakthrough science only matters when it reaches people.
Too many promising therapies get stuck between the lab and the patient, held back by manufacturing that can’t scale, slow clinical development and data that’s hard to use. So we back the founders solving those problems, alongside the therapies themselves.
Teams creating new treatments, from personalised cell therapies for solid tumours to RNA and small-molecule medicines.
Platforms that make cell and gene therapies possible to produce reliably, at scale and at a sensible cost.
Tools that speed up discovery and clinical research, from AI-simulated cells to real-world evidence.
We love meeting founders and scientists with a clear path from breakthrough to real-world impact, a problem that genuinely matters, and the ambition to build something that lasts.
If that sounds like you, we’d like to hear from you.
Cell and gene therapy, drug discovery and clinical research.
Patient capital, deep expertise, hands-on support.
Our permanent capital means we’ll never push you to sell early.
We help found and shape companies from first principles, not just fund them.
Our experience, coaching and network of experts are yours to use.
Our domain expertise helps you make better decisions, faster.
Founders and co-investors, we’d love to hear from you.